Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel

Ariel Perez Perez, MD, Christina A Bachmeier, PharmD, Renee Smilee, Albert J Ribickas, Aleksandr Lazaryan, MDPhDMPH, Julio C. Chavez, MD, Claudio Anasetti, MD, Bijal Shah, MD, Farhad Khimani, MBBS, Taiga Nishihori, MD, Marco L. Davila, MD PhD, Frederick L. Locke, MD, Michael D. Jain, MDPhD, Hien D. Liu, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-143336

Published: 2020

Journal Articles

Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma

Michael D. Jain, MD PhD, Hua Zhao, Reginald Atkins, Meghan A Menges, Crystal R Pope, Rawan Faramand, MD, Sae Bom Lee, Justin C. Boucher, PhD, Hiroshi Kotani, MD PhD, Christina A Bachmeier, PharmD, Julio Chavez, Bijal Shah, MD, Mohammad Hussaini, MD, Ricardo J Gonzalez, MD, John E Mullinax, MD PhD, Marco L. Davila, MD PhD, Frederick L. Locke, MD

Blood (2019) 134 (Supplement_1): 2885.

https://doi.org/10.1182/blood-2019-131041

Published: 2019

Journal Articles

The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy

Michael D. Jain, MD PhD, Rawan Faramand, MD, Verena Staedtke, MD PhD, Renyuan Bai, MBBS, Sae Bom Lee, Hiroshi Kotani, MD PhD, Kayla Reid, Kristen Spitler, Julio Chavez, Bijal Shah, MD, Christina A Bachmeier, PharmD, Marian Dam, ARNP, Brigett Brandjes, PA, Ricardo J Gonzalez, MD, John E Mullinax, MD PhD, Xuefeng Wang, PhD, Mohammad Hussaini, MD, Frederick L. Locke, MD, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 4105.

https://doi.org/10.1182/blood-2019-127305

Published: 2019

Journal Articles

The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Sepideh Mokhtari, MD, Justin M Asquith, MD, Christina A Bachmeier, PharmD, Michael D. Jain, MD PhD, Peter Forsyth, MD, Frederick L. Locke, MD, Youngchul Kim, PhD, Aleksandr Lazaryan, MD PhD MPH

Blood (2019) 134 (Supplement_1): 5627.

https://doi.org/10.1182/blood-2019-122343

Published: 2019

Journal Articles

Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma

Hamza Hashmi, MD, Alicia Darwin, Christina A Bachmeier, PharmD, Julio Chavez, Bijal Shah, MD, Javier Pinilla Ibarz, MD PhD, Taiga Nishihori, MD, Farhad Khimani, MD, Aleksandr Lazaryan, MDPhDMPH, Hien D. Liu, MD, Marco L. Davila, MD PhD, Frederick L. Locke, MD, Michael D. Jain, MD PhD

Blood (2019) 134 (Supplement_1): 1612.

https://doi.org/10.1182/blood-2019-126148

Published: 2019

Journal Articles

Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements

Rawan Faramand, MD, Hiroshi Kotani, MD PhD, Dylan Morrissey, Bin Yu, Frederick L. Locke, MD, Michael D. Jain, MDPhD, Julio C. Chavez, MD, Xuefeng Wang, PhD, Asmita Mishra, MD, Christina A Bachmeier, PharmD, Renier J. Brentjens, MD PhD, Sarah Yoo, Jae H. Park, MD, Marco L. Davila, MD PhD

Blood (2018) 132 (Supplement 1): 95.

https://doi.org/10.1182/blood-2018-99-116539

Published: 2018

NARROW

Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel

Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma

The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy

The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma

Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements

Email alerts

ASH Publications

American Society of Hematology

Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel

Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma

The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy

The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma

Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only